ASTERDM - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.3
| Stock Code | ASTERDM | Market Cap | 39,103 Cr. | Current Price | 755 ₹ | High / Low | 777 ₹ |
| Stock P/E | 119 | Book Value | 84.3 ₹ | Dividend Yield | 0.66 % | ROCE | 10.8 % |
| ROE | 8.94 % | Face Value | 10.0 ₹ | DMA 50 | 699 ₹ | DMA 200 | 637 ₹ |
| Chg in FII Hold | -1.28 % | Chg in DII Hold | 1.45 % | PAT Qtr | 85.3 Cr. | PAT Prev Qtr | 58.9 Cr. |
| RSI | 64.9 | MACD | 20.4 | Volume | 6,49,689 | Avg Vol 1Wk | 5,56,022 |
| Low price | 519 ₹ | High price | 777 ₹ | PEG Ratio | 5.05 | Debt to equity | 0.31 |
| 52w Index | 91.5 % | Qtr Profit Var | 3.43 % | EPS | 5.17 ₹ | Industry PE | 48.6 |
📊 Financial Overview:
ASTERDM shows moderate fundamentals with quarterly PAT at ₹85.3 Cr., up from ₹58.9 Cr., reflecting earnings growth. ROCE at 10.8% and ROE at 8.94% are modest, indicating average capital efficiency. Debt-to-equity at 0.31 is manageable, though leverage is slightly elevated. EPS stands at ₹5.17, supported by profitability, but margins remain thin. Cash flows appear stable, though efficiency ratios need improvement.
💹 Valuation Indicators:
The stock trades at a very high P/E of 119, far above the industry average of 48.6, suggesting significant overvaluation. P/B ratio is ~9.0 (755 ÷ 84.3), which is elevated. PEG ratio of 5.05 indicates poor valuation relative to growth prospects. Dividend yield of 0.66% provides minor investor returns. Intrinsic value appears lower than current price, limiting upside potential.
🏢 Business Model & Advantage:
ASTERDM operates in healthcare services, with hospitals and clinics across India and the Middle East. Its competitive advantage lies in brand presence, diversified healthcare offerings, and regional expansion. Institutional sentiment is mixed, with FIIs reducing holdings (-1.28%) while DIIs increased (+1.45%), reflecting cautious optimism.
📈 Entry Zone:
Technically, support lies near ₹699 (50 DMA) and ₹637 (200 DMA). A cautious entry zone would be between ₹700–₹730 if valuations cool down. Long-term investors may hold given sector growth, but stretched valuations warrant caution.
Positive
- 📌 Quarterly PAT growth (₹85.3 Cr. vs ₹58.9 Cr.).
- 📌 EPS of ₹5.17 reflects profitability.
- 📌 DII holdings increased (+1.45%), showing domestic investor confidence.
- 📌 Strong healthcare brand with regional presence.
Limitation
- ⚠️ Very high P/E (119) compared to industry average (48.6).
- ⚠️ Elevated P/B ratio (~9.0).
- ⚠️ PEG ratio (5.05) suggests poor valuation relative to growth.
- ⚠️ ROCE (10.8%) and ROE (8.94%) are modest.
- ⚠️ FII holdings decreased (-1.28%).
Company Negative News
- 📰 Concerns over stretched valuations and reduced foreign investor confidence.
Company Positive News
- 📰 Quarterly profits improved steadily.
- 📰 Strong domestic institutional inflows reflect confidence in long-term prospects.
Industry
- 🌐 Healthcare industry benefits from rising demand for hospitals, diagnostics, and clinics in India and abroad.
- 🌐 Industry P/E at 48.6 reflects growth potential, while ASTERDM trades at a steep premium.
Conclusion
✅ ASTERDM has shown profit growth and maintains industry relevance with a strong healthcare brand. However, weak return ratios and extreme valuations make it risky for fresh entry. Entry is advisable near ₹700–₹730 with caution. Long-term holding requires improvement in efficiency and moderation in valuation multiples to justify sustained investment.
For deeper insights, you could explore a peer comparison or a healthcare sector outlook to complement this analysis.